DNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes. In an interview with Targeted Oncology, Rutika Mehta, MD, ...

In the rapidly shifting landscape of multiple myeloma treatment, the roadmap for a patient diagnosed in 2026 looks vastly different than it did even a decade ago. In a recent interview with CURE, Dr.

BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial ...

This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoformsNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer ...

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program ...

Lonial emphasizes that the EXCALIBER-RRMM trial is a test case for a new regulatory framework. The study utilizes dual primary end points to satisfy both accelerated and full approval requirements: ...

For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For survivor Julie Cohen, that search led her to the front lines of medical ...

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for February 2026, includes Reg.-NMS Execution Statistics ...

Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 ...

Regulatory emphasis shifts from ORR and response duration to MRD negativity and CR as surrogate endpoints intended to shorten development timelines by capturing deeper molecular responses. MRD ...